Skip to content
drillr.ai
Sign up

COYA

Coya Therapeutics, Inc.

NASDAQ · Healthcare · Biotechnology · US

$3.08
−0.96%
Ask drillr

  • Oct 14, 2026, 12:00 UTC

    Coya Therapeutics announced plans to initiate an open-label extension of its Phase 2/3 ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis, in response to requests from trial investigators.

    Source:

  • Aug 11, 2026, 12:00 UTC

    Coya Therapeutics reported its financial results for the second quarter of 2026 and provided a corporate update.

    Source: